BioSig Technologies to Acquire PediaTrust, LLC
Ticker: STEX · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1.00, $1 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, m&a, healthcare
Related Tickers: BSGM
TL;DR
BioSig buying PediaTrust to enter the pediatric market, deal expected Q1 2025.
AI Summary
BioSig Technologies, Inc. announced on October 24, 2024, that it has entered into a definitive agreement to acquire PediaTrust, LLC. The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions. This strategic move aims to expand BioSig's market presence and product offerings in the pediatric healthcare sector.
Why It Matters
This acquisition signifies BioSig's strategic expansion into the pediatric market, potentially broadening its revenue streams and market share.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies.
Key Players & Entities
- BioSig Technologies, Inc. (company) — Registrant
- PediaTrust, LLC (company) — Acquisition Target
- October 24, 2024 (date) — Date of Agreement
- First Quarter of 2025 (date) — Expected Closing Period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on the "Other Events" of BioSig Technologies, Inc., specifically announcing a definitive agreement to acquire PediaTrust, LLC.
When is the acquisition of PediaTrust, LLC expected to close?
The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions.
What is the strategic rationale behind BioSig Technologies acquiring PediaTrust, LLC?
While not explicitly detailed in the provided text, the context suggests BioSig is expanding its market presence and product offerings, likely into the pediatric healthcare sector given PediaTrust's name.
What is the filing date of this 8-K report?
The filing date of this 8-K report is October 29, 2024.
What is the earliest event date reported in this filing?
The earliest event date reported in this filing is October 24, 2024, which is the date of the earliest event reported.
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-10-29 13:30:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
- $1.00 — y did not meet the minimum bid price of $1.00 per share required by the Listing Rules
- $1 — e of the Company's security is at least $1 for a minimum of ten consecutive busine
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-042801.txt ( ) — 207KB
- bsgm-20241024.xsd (EX-101.SCH) — 3KB
- bsgm-20241024_lab.xml (EX-101.LAB) — 33KB
- bsgm-20241024_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: October 29, 2024 By: /s/ Anthony Amato Name: Anthony Amato Title: Chief Executive Officer